RBC Capital Upgrades Neumora Therapeutics to Outperform
RBC Capital raises Neumora Therapeutics to Outperform, citing new growth opportunities beyond neurology and promising early data in multiple markets.
/ 2 items
RBC Capital raises Neumora Therapeutics to Outperform, citing new growth opportunities beyond neurology and promising early data in multiple markets.
Guggenheim upgrades Neumora to Buy with $14 target after impressive preclinical obesity data shows up to 26% weight loss with NLRP3 inhibitor NMRA-215.